Skip to main content
. Author manuscript; available in PMC: 2012 Sep 15.
Published in final edited form as: Clin Cancer Res. 2011 Aug 3;17(18):5945–5952. doi: 10.1158/1078-0432.CCR-11-0970

Figure 1.

Figure 1

Generation of Id VL peptide-specific T cells from 10 normal donors (ND1–10). (A) IFN-γ secretion by U266 myeloma cell line VL peptide-specific CTLs after stimulation with peptide-pulsed T2 cells or HIV-Gag77 peptide-pulsed T2 cells (negative control). Influenza A virus M1(58–66) peptide was used as a positive control. Id VL peptide sequences and characteristics are shown in Table.1 (B) IFN-γ secretion by primary B-cell tumor-derived VL peptide specific CTLs against peptide pulsed or HIV-Gag77 peptide-pulsed T2 cells. (C) Intracellular cytokine staining assay of peptide-specific CTLs in response to VL peptide or HIV-Gag77 peptide-pulsed T2 cells. * indicates P<0.05.